DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

Pharmacopidemiology and Drug Safety is a prestigious academic journal published by Wiley, dedicated to exploring the field of pharmacology and epidemiological studies since its inception in 1992. With its ISSN 1053-8569 and E-ISSN 1099-1557, the journal has achieved notable recognition, ranking Q2 in Epidemiology and Q1 in Medical Pharmacology in the 2023 category quartiles. Its Scopus rankings further enhance its reputation, placing it at 105th in the field of pharmacology and at 63rd in epidemiology, reflecting its commitment to publishing high-quality research that informs clinical practices and public health policies. Although it operates under a subscription model rather than open access, Pharmacopidemiology and Drug Safety plays a critical role in disseminating vital knowledge regarding drug safety and effectiveness, making it an essential resource for researchers, professionals, and students looking to stay at the forefront of advancements in the medical field.

Therapeutics and Clinical Risk Management is a pioneering journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of medication safety, pharmacology, and clinical risk management through rigorous research and comprehensive reviews. With an impact factor that demonstrates its significance within various disciplines, this Open Access journal has been instrumental since its inception in 2006, promoting the dissemination of knowledge to a global audience without barriers. With its reach spanning categories such as Pharmacology, Medicine, and Chemical Health and Safety, it champions innovative practices and risk assessment methodologies. The journal is recognized in the Q2 quartile for multiple related categories and excels in rank within its field, highlighting its influential contributions to safety and therapeutic practices. By prioritizing the sharing of impactful research, Therapeutics and Clinical Risk Management serves as an indispensable resource for researchers, professionals, and students aiming to enhance clinical outcomes and mitigate risks in therapeutic paradigms.

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE, published by IOS Press, serves as an essential platform for advancing the understanding of risk and safety within the medical domain. With an ISSN of 0924-6479 and E-ISSN of 1878-6847, this journal has been dedicated to fostering critical discourse since its inception in 1990, reflecting a continuous commitment to the field through 2024. Positioned within the Q4 category in Health Policy and Q3 in Medicine (miscellaneous) and Public Health, Environmental and Occupational Health, the journal provides valuable insights, empirical research, and theoretical analyses that speak to the diverse challenges faced in medical safety and risk management. Although it operates under a subscription model, the journal remains a vital resource for researchers, healthcare professionals, and students alike, facilitating the exchange of innovative ideas and best practices in health risk assessment. With Scopus ranks indicating its role as a key contributor in its categories, the INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE continues to shape the landscape of medical safety and policy discussions around the globe.

DRUG SAFETY is a premier academic journal published by ADIS INT LTD, dedicated to the critical field of pharmacology and toxicology. Since its inception in 1990, the journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals by providing high-quality, peer-reviewed articles that inform and advance the understanding of drug safety and efficacy. With an impressive impact factor and its current Q1 categorization in Pharmacology across various sub-disciplines, DRUG SAFETY is ranked among the top journals in its field, reflecting its commitment to excellence in scientific research. The journal features a diverse range of studies, reviews, and case reports addressing contemporary issues in drug safety, making it an invaluable tool for academia and industry alike. Although it is not an open-access journal, the content is accessible to subscribers and institutions, ensuring that essential findings in drug safety reach the widest audience possible. As the field evolves, DRUG SAFETY remains at the forefront, driving innovation and improving regulatory practices worldwide.

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

The American Journal of Therapeutics is a prominent academic journal published by Lippincott Williams & Wilkins, specializing in the fields of medicine and pharmacology. With a rich history originating from 1960 and a commitment to advancing therapeutic knowledge through peer-reviewed research, this journal serves as a vital resource for professionals, researchers, and students alike. Its strong impact factor, alongside its classification in the Q2 and Q3 quartiles for diverse categories in medicine and pharmacology, underscores its significance in the academic community. The journal engages with the latest findings and innovations in therapeutic approaches, offering a platform for discussion and dissemination of research that addresses critical healthcare challenges. Although it operates under a traditional subscription model, the journal aims to foster open discourse within the therapeutic landscape, making it essential reading for those dedicated to enhancing patient care and pharmaceutical practices.

Therapeutic Advances in Drug Safety is a prestigious open-access journal published by SAGE Publications Ltd that has made significant strides in the field of pharmacology since its inception in 2010. With an impressive impact factor that places it in the Q1 category for Pharmacology (medical), this journal ranks 61st out of 272 in Scopus, showcasing its global influence and commitment to advancing drug safety research. Based in the United Kingdom, it aims to bridge the critical gap between pharmacological innovation and clinical application, offering a platform for the dissemination of groundbreaking research, case studies, and expert reviews. Since adopting an Open Access model in 2019, the journal has significantly increased its reach, ensuring that vital findings in drug safety are accessible to researchers, healthcare professionals, and educators worldwide. As the field of drug safety continues to evolve, Therapeutic Advances in Drug Safety remains an essential resource for those dedicated to enhancing safe therapeutic practices and patient outcomes.

Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.